Eli Lilly (LLY) Acquires Centessa for $7.8 Billion

Eli Lilly and Company (LLY) announced the acquisition of Centessa for $7.8 billion, with analyst estimates suggesting a market potential for Centessa's drugs of up to $20 billion. The company's stock rose 4.6% over the past five days and is up 18.6% year-over-year, despite a year-to-date decline of 13.4%. Additionally, on April 1, the FDA approved LLY's GLP-1 weight loss pill, Foundayo. Eli Lilly's aggressive investment marks its commitment to tackling challenging medical issues, which may enhance its market position moving forward.